LAVA Therapeutics NV isa clinical stage immuno-oncology company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LVTX is expected to report earnings to rise 130.77% to -30 cents per share on August 26
Q2'25
Est.
$-0.30
Q1'25
Beat
by $0.19
Q4'24
Beat
by $0.16
Q3'24
Missed
by $0.13
Q2'24
Beat
by $0.02
The last earnings report on May 14 showed earnings per share of -12 cents, beating the estimate of -31 cents. With 221.44K shares outstanding, the current market capitalization sits at 40.25M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. LVTX showed earnings on May 14, 2025. You can read more about the earnings report here.